Targeting the Hedgehog pathway in cancer: can the spines be smoothened?

Clin Cancer Res. 2011 Apr 15;17(8):2071-3. doi: 10.1158/1078-0432.CCR-11-0211. Epub 2011 Mar 2.

Abstract

Aberrant Hedgehog (Hh) pathway signaling has been suggested to play a role in the development of multiple solid tumors and hematologic malignancies. GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.

Publication types

  • Comment

MeSH terms

  • Anilides / metabolism
  • Anilides / pharmacokinetics
  • Anilides / therapeutic use*
  • Dose-Response Relationship, Drug
  • Gene Expression Regulation, Neoplastic / drug effects
  • Hedgehog Proteins / antagonists & inhibitors*
  • Hedgehog Proteins / metabolism
  • Humans
  • Metabolic Clearance Rate
  • Neoplasm Metastasis
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Orosomucoid / metabolism
  • Protein Binding
  • Pyridines / metabolism
  • Pyridines / pharmacokinetics
  • Pyridines / therapeutic use*
  • Signal Transduction / drug effects*
  • Transcription Factors / genetics
  • Treatment Outcome
  • Zinc Finger Protein GLI1

Substances

  • Anilides
  • GLI1 protein, human
  • Hedgehog Proteins
  • HhAntag691
  • Orosomucoid
  • Pyridines
  • Transcription Factors
  • Zinc Finger Protein GLI1